Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
- PMID: 33002206
- PMCID: PMC7854940
- DOI: 10.3322/caac.21638
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
Abstract
Cancer is a disease of aging and, as the world's population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country. Despite this, older patients remain vastly underrepresented in research that sets the standards for cancer treatments. Consequently, most of what we know about cancer therapeutics is based on clinical trials conducted in younger, healthier patients, and effective strategies to improve clinical trial participation of older adults with cancer remain sparse. For this systematic review, the authors evaluated published studies regarding barriers to participation and interventions to improve participation of older adults in cancer trials. The quality of the available evidence was low and, despite a literature describing multifaceted barriers, only one intervention study aimed to increase enrollment of older adults in trials. The findings starkly amplify the paucity of evidence-based, effective strategies to improve participation of this underrepresented population in cancer trials. Within these limitations, the authors provide their opinion on how the current cancer research infrastructure must be modified to accommodate the needs of older patients. Several underused solutions are offered to expand clinical trials to include older adults with cancer. However, as currently constructed, these recommendations alone will not solve the evidence gap in geriatric oncology, and efforts are needed to meet older and frail adults where they are by expanding clinical trials designed specifically for this population and leveraging real-world data.
Keywords: clinical trials; older adults; oncology; patient participation; patient selection; practice patterns.
© 2020 American Cancer Society.
Conflict of interest statement
Conflict of interest Disclosures:
Dr. Kimmick reports personal fees and non-financial support from Eisai, Boehringer Ingelheim, and Genomic Health; personal fees from Agendia; non-financial support from Seattle Genetics, Novartis, and Pfizer; grants from Bionovo, PUMA, and Roche, outside the submitted work.
Dr. Sedrak reports grants from National Institute on Aging (NIA R03AG064377), National Cancer Institute (NCI K12CA001727), Waisman Innovation Fund, and Circle 1500, during the conduct of the study; grants from Seattle Genetics, Eli Lilly, Novartis, and Pfizer Foundation, outside the submitted work;
Dr. Wildes reports research funding from Janssen and consulting fees from Carevive Systems and Seattle Genetics.
The remaining authors report no conflicts of interest.
References
-
- Noone A, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2015. Bethesda, MD: National Cancer Institute; 2017.
-
- Ferlay JE, Lam F, Colombet M, et al. Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer; 2018.
-
- Singh H, Kanapuru B, Smith C, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US Food and Drug Administration. J Clin Oncol. 2017;35.
-
- Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–4631. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous